Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease

Laboratory Investigation

Volumn 94, Issue 10, 2014, Pages 1161-1172

  Postupna, Nadia O ^a   Dirk Keene, C ^a   Latimer, Caitlin ^a   Sherfield, Emily E ^a   Van Gelder, Rachel D ^a,b   Ojemann, Jeffrey G ^b   Montine, Thomas J ^a   Darvas, Martin ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMYLOID BETA PROTEIN; DOPAMINE; ALPHA SYNUCLEIN; CATECHOLAMINE; DOPAMINE TRANSPORTER; SLC17A7 PROTEIN, HUMAN; VESICULAR GLUTAMATE TRANSPORTER 1;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; BRAIN SYNAPTOSOME; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; MOUSE; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POSTMORTEM CHANGE; PRIORITY JOURNAL; VERY ELDERLY; ANIMAL; CHEMISTRY; PATHOLOGY; SYNAPTOSOME;

AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CATECHOLAMINES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; LEWY BODY DISEASE; MALE; MICE; SYNAPTOSOMES; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84921775165     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.103     Document Type: Article

References (53)

1. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2013;246:72-83.
2. Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 2009;24: 114-125.
3. Collins LM, Toulouse A, Connor TJ, et al. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012;62:2154-2168.
4. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-598.
5. Kurz A, Perneczky R. Neurobiology of cognitive disorders. Curr Opin Psychiatry 2009;22:546-551.
6. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006;248: 255-258.
7. Bellucci A, Zaltieri M, Navarria L, et al. From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012;1476:183-202.
8. Scott DA, Tabarean I, Tang Y, et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 2010;30:8083-8095.
9. Milatovic D, Montine TJ, Zaja-Milatovic S, et al. Morphometric analysis in neurodegenerative disorders. Curr Protoc Toxicol 2010; Chapter 12:Unit 12, 16.
10. Meinertzhagen IA, Takemura SY, Lu Z, et al. From form to function: the ways to know a neuron. J Neurogenet 2009;23:68-77.
11. Booth RF, Clark JB. A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain. Biochem J 1978;176:365-370.
12. Gray EG, Whittaker VP. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homo-genization and centrifugation. J Anat 1962;96:79-88.
13. Hebb CO, Whittaker VP. Intracellular distributions of acetylcholine and choline acetylase. J Physiol 1958;142:187-196.
14. Arold S, Sullivan P, Bilousova T, et al. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Acta Neuropathol 2012;123:39-52.
15. Henkins KM, Sokolow S, Miller CA, et al. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol 2012;22:826-833.
16. Tai LM, Bilousova T, Jungbauer L, et al. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 2013;288: 5914-5926.
17. Cholerton B, Larson EB, Baker LD, et al. Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis 2013;36:699-709.
18. Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis 2013;3:205-214.
19. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
20. Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009;256(Suppl 3):270-279.
21. White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 2002;977:9-23.
22. Gylys KH, Fein JA, Cole GM. Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry. J Neurosci Res 2000;61:186-192.
23. Montine KS, Montine TJ. Anatomic and clinical pathology of cognitive impairment and dementia. J Alzheimers Dis 2013;33(Suppl 1): S181-S184.
24. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8: 1-13.
25. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1-11.
26. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
27. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
28. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
29. Luquet S, Perez FA, Hnasko TS, et al. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 2005;310:683-685.
30. Sokolow S, Luu SH, Nandy K, et al. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiol Dis 2012;45: 381-387.
31. Dunkley PR, Jarvie PE, Heath JW, et al. A rapid method for isolation of synaptosomes on Percoll gradients. Brain Res 1986;372:115-129.
32. Nagy A, Delgado-Escueta AV. Rapid preparation of synaptosomes from mammalian brain using nontoxic isoosmotic gradient material (Percoll). J Neurochem 1984;43:1114-1123.
33. Melchitzky DS, Lewis DA. Tyrosine hydroxylase-and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular-and laminar-specific dopamine innervation. Neuropsychopharmacology 2000;22:466-472.
34. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30:194-202.
35. Gylys KH, Fein JA, Yang F, et al. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol 2004;165:1809-1817.
36. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
37. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013;136(Pt 7):2228-2238.
38. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4: 160-164.
39. Chen KH, Reese EA, Kim HW, et al. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis 2011;26:755-766.
40. Price DL, Rockenstein E, Ubhi K, et al. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS One 2010;5:e14020.
41. Blandini F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 2010;25: 65-71.
42. Brucke T, Djamshidian S, Bencsits G, et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000;247(Suppl 4):IV/2-IV/7.
43. Chassain C, Bielicki G, Keller C, et al. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed 2010;23:547-553.
44. Gao HC, Zhu H, Song CY, et al. Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat. Mol Neurobiol 2013;47:123-130.
45. Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 2013;36:543-554.
46. Ahmed I, Bose SK, Pavese N, et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011;134(Pt 4):979-986.
47. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry; advance online publication, 3 July 2013; doi:10.1016/j.jagp.2013.03.001; pii: S1064-7481(13)00168-1 (e-pub ahead of print).
48. Shi M, Huber BR, Zhang J. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 2010;20:660-671.
49. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57-71.
50. Bohnen NI, Albin RL. Cholinergic denervation occurs early in Parkinson disease. Neurology 2009;73:256-257.
51. Brooks D, Halliday GM. Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull 2009;78:97-104.
52. Halliday GM. Thalamic changes in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S152-S155.
53. Hirsch EC, Graybiel AM, Duyckaerts C, et al. Neuronal loss in the peduncul-opontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 1987;84:5976-5980.